Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales

Executive Summary

Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results

You may also be interested in...



Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings

Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor

Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot

Pfizer's $60 bil. offer for Pharmacia could be a landmark event in the remaking of the Pfizer image, as well as a large-scale strategic move to broaden Pfizer's product line into new specialties and deepen the pipeline

Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug

Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel